(ILMN) Illumina - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4523271090

Sequencers, Arrays, Reagents, Kits, Services

Stock: Life Sciences Tools & Services
Age 25.5y

MCap 21,772m
Avg Vol 1.68M (252M USD)

Beta 1.095
Volatility 42.80%

EPS (Earnings per Share)

EPS CAGR: -60.17%
EPS Trend: 28.2%

Last SUE: -4.00
Qual. Beats: 0

Revenue

Rev. CAGR: -2.68%
Rev. Trend: -75.7%

Last SUE: 1.05
Qual. Beats: 1

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	42.8%
Value at Risk 5%th	66.2%
Relative Tail Risk	-5.99%

Reward TTM
Sharpe Ratio	0.38
Alpha	-8.95
CAGR/Max DD	-0.15

Character TTM
Hurst Exponent	0.320
Beta	1.095
Beta Downside	0.876

Drawdowns 3y
Max DD	68.94%
Mean DD	41.31%
Median DD	42.85%

Description: ILMN Illumina January 02, 2026

Illumina (NASDAQ: ILMN) develops and sells sequencing- and array-based platforms and consumables for genomic analysis across a global customer base that includes research institutions, clinical labs, pharma/biotech firms, and consumer-genomics companies. Its product portfolio spans next-generation sequencing instruments, whole-genome and targeted-sequencing kits, genotyping arrays, and non-invasive prenatal testing solutions, supported by reagent kits, flow cells, and library-prep services.

Key recent metrics: 2023 revenue reached $5.6 billion, up ~9 % YoY, driven by a 15 % increase in consumables sales as sequencing-throughput volumes rise. The company’s cost-per-genome has fallen below $200, reinforcing its competitive edge in the rapidly expanding clinical-diagnostics market, where NGS adoption is projected to grow at a CAGR of ~20 % through 2030. A notable sector driver is the surge in personalized-medicine pipelines, which fuels demand for high-throughput, low-error-rate sequencing platforms.

For a deeper, data-focused assessment of Illumina’s valuation dynamics, you may find the analytical tools on ValueRay worth exploring.

Piotroski VR‑10 (Strict, 0-10) 8.0

Net Income: 703.0m TTM > 0 and > 6% of Revenue
FCF/TA: 0.16 > 0.02 and ΔFCF/TA 7.22 > 1.0
NWC/Revenue: 19.45% < 20% (prev 31.85%; Δ -12.39% < -1%)
CFO/TA 0.18 > 3% & CFO 1.12b > Net Income 703.0m
Net Debt (1.53b) to EBITDA (1.29b): 1.18 < 3
Current Ratio: 1.43 > 1.5 & < 3
Outstanding Shares: last quarter (157.0m) vs 12m ago -1.88% < -2%
Gross Margin: 66.20% > 18% (prev 0.64%; Δ 6556 % > 0.5%)
Asset Turnover: 70.33% > 50% (prev 73.00%; Δ -2.67% > 0%)
Interest Coverage Ratio: 8.16 > 6 (EBITDA TTM 1.29b / Interest Expense TTM 125.0m)

Altman Z'' 1.42

A: 0.14 (Total Current Assets 2.80b - Total Current Liabilities 1.96b) / Total Assets 6.18b
B: -0.12 (Retained Earnings -726.0m / Total Assets 6.18b)
C: 0.17 (EBIT TTM 1.02b / Avg Total Assets 6.10b)
D: -0.19 (Book Value of Equity -736.0m / Total Liabilities 3.80b)
Altman-Z'' Score: 1.42 = BB

Beneish M -3.12

DSRI: 1.08 (Receivables 751.0m/715.0m, Revenue 4.29b/4.39b)
GMI: 0.97 (GM 66.20% / 63.94%)
AQI: 0.93 (AQ_t 0.36 / AQ_t-1 0.39)
SGI: 0.98 (Revenue 4.29b / 4.39b)
TATA: -0.07 (NI 703.0m - CFO 1.12b) / TA 6.18b)
Beneish M-Score: -3.12 (Cap -4..+1) = AA

ValueRay F-Score (Strict, 0-100) 71.47

1. Piotroski: 8.0pt
2. FCF Yield: 4.32%
3. FCF Margin: 23.49%
4. Debt/Equity: 1.08
5. Debt/Ebitda: 1.18
6. ROIC - WACC: 7.00%
7. RoE: 29.98%
8. Revenue Trend: -75.73%
9. EPS Trend: 28.22%

What is the price of ILMN shares?

As of January 26, 2026, the stock is trading at USD 150.28 with a total of 2,764,801 shares traded.
Over the past week, the price has changed by +2.11%, over one month by +11.36%, over three months by +49.76% and over the past year by +8.86%.

Is ILMN a buy, sell or hold?

Illumina has received a consensus analysts rating of 3.68. Therefor, it is recommend to hold ILMN.

Strong Buy: 7
Buy: 5
Hold: 11
Sell: 2
Strong Sell: 0

What are the forecasts/targets for the ILMN price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	132.1	-12.1%
Analysts Target Price	132.1	-12.1%
ValueRay Target Price	157.6	4.9%

ILMN Fundamental Data Overview January 21, 2026

P/E Trailing = 31.7601
P/E Forward = 28.3286
P/S = 5.0773
P/B = 9.0903
P/EG = 0.622
Revenue TTM = 4.29b USD
EBIT TTM = 1.02b USD
EBITDA TTM = 1.29b USD
Long Term Debt = 994.0m USD (from longTermDebt, last quarter)
Short Term Debt = 1.08b USD (from shortTermDebt, last quarter)
Debt = 2.58b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.53b USD (from netDebt column, last quarter)
Enterprise Value = 23.30b USD (21.77b + Debt 2.58b - CCE 1.05b)
Interest Coverage Ratio = 8.16 (Ebit TTM 1.02b / Interest Expense TTM 125.0m)
EV/FCF = 23.14x (Enterprise Value 23.30b / FCF TTM 1.01b)
FCF Yield = 4.32% (FCF TTM 1.01b / Enterprise Value 23.30b)
FCF Margin = 23.49% (FCF TTM 1.01b / Revenue TTM 4.29b)
Net Margin = 16.40% (Net Income TTM 703.0m / Revenue TTM 4.29b)
Gross Margin = 66.20% ((Revenue TTM 4.29b - Cost of Revenue TTM 1.45b) / Revenue TTM)
Gross Margin QoQ = 67.59% (prev 65.63%)
Tobins Q-Ratio = 3.77 (Enterprise Value 23.30b / Total Assets 6.18b)
Interest Expense / Debt = 1.94% (Interest Expense 50.0m / Debt 2.58b)
Taxrate = 31.82% (70.0m / 220.0m)
NOPAT = 695.5m (EBIT 1.02b * (1 - 31.82%))
Current Ratio = 1.43 (Total Current Assets 2.80b / Total Current Liabilities 1.96b)
Debt / Equity = 1.08 (Debt 2.58b / totalStockholderEquity, last quarter 2.38b)
Debt / EBITDA = 1.18 (Net Debt 1.53b / EBITDA 1.29b)
Debt / FCF = 1.52 (Net Debt 1.53b / FCF TTM 1.01b)
Total Stockholder Equity = 2.35b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.53% (Net Income 703.0m / Total Assets 6.18b)
RoE = 29.98% (Net Income TTM 703.0m / Total Stockholder Equity 2.35b)
RoCE = 30.55% (EBIT 1.02b / Capital Employed (Equity 2.35b + L.T.Debt 994.0m))
RoIC = 16.04% (NOPAT 695.5m / Invested Capital 4.34b)
WACC = 9.04% (E(21.77b)/V(24.35b) * Re(9.95%) + D(2.58b)/V(24.35b) * Rd(1.94%) * (1-Tc(0.32)))
Discount Rate = 9.95% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.63%
[DCF Debug] Terminal Value 74.46% ; FCFF base≈822.6m ; Y1≈826.5m ; Y5≈883.5m
Fair Price DCF = 74.49 (EV 12.91b - Net Debt 1.53b = Equity 11.38b / Shares 152.8m; r=9.04% [WACC]; 5y FCF grow 0.0% → 2.90% )
EPS Correlation: 28.22 | EPS CAGR: -60.17% | SUE: -4.0 | # QB: 0
Revenue Correlation: -75.73 | Revenue CAGR: -2.68% | SUE: 1.05 | # QB: 1
EPS next Quarter (2026-03-31): EPS=1.13 | Chg30d=+0.011 | Revisions Net=+1 | Analysts=11
EPS next Year (2026-12-31): EPS=5.07 | Chg30d=+0.059 | Revisions Net=+2 | Growth EPS=+7.5% | Growth Revenue=+2.7%

Additional Sources for ILMN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle